Partnering
Cascade Prodrug is seeking investment in CPD100 and CPD100Li and is open to discussions with investors and potential pharmaceutical partners with an interest in novel targeted therapies in the ophthalmic and oncology space.
Cascade’s current strategy is focused on bringing novel hypoxia-activated therapies into clinical development with an initial focus on CPD100: a potential first-in- class targeted therapy in wet AMD delivered by a highly localized suprachoroidal injection. This represents a significantly differentiated approach from the existing wet AMD commercial and clinical stage pipeline dominated by anti-VEGF therapeutics delivered by intravitreal injection.
An additional opportunity exists with CPD100Li, a liposomal formulation for IV systemic therapy in patients with tumors prone to hypoxia such as pancreatic and pediatric low- grade glioma.
We are currently exploring investment & partnership opportunities to further development of CPD100 through late preclinical development, IND enabling studies and into the clinic.
For further inquiries, please contact partnering@cascadeprodrug.com.